

ADJUVANT BISPHOSPHONATES

GUIDANCE

NICE 2018 (2020)

Bisphosphonates (zoledronic acid or sodium clodronate)

- OFFER Post-menopausal (natural or induced) N1+ invasive breast cancer
- CONSIDER bisphosphonates N0 but high rx recurrence
- DISCUSSION includes jaw and external auditory canal osteonecrosis and atypical femoral fractures

ABS advocate bisphosphonates in post-menopausal women and it would be fair to argue for this!

There is also guidance on who gets Bisphosphonates when starting AI – see the great flow diagram in the guidance section “Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK expert group”. Here we will deal only with its use as an adjuvant therapy rather than bone health.

This slide summarises some of the evidence, papers can be found in the literature folder:

